Cannabis and Hallucinations: Studies in Human Subjects

  • Paul Allen
  • Toby T. Winton-Brown


Cannabis is the world’s most widely used illicit drug. Although the effects of cannabis on perception are well documented, little is known about their neural basis or how these may contribute to the formation of psychotic symptoms, particularly hallucinations. This chapter examines the relationship between cannabis, psychosis and hallucinations, and describes the small number of studies that have directly examined the effects of cannabis and Δ-9-THC on sensory cortices.


Psychotic Symptom Superior Temporal Gyrus Visual Hallucination Cannabis User Auditory Hallucination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Allen, P., Larøi, F., McGuire, P. K., & Aleman, A. (2008). The hallucinating brain: A review of structural and functional neuroimaging studies of hallucinations. Neuroscience and Biobehavioral Reviews, 32(1), 175–191.PubMedCrossRefGoogle Scholar
  2. Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004). Causal association between ­cannabis and psychosis: Examination of the evidence. The British Journal of Psychiatry, 184, 110–117.PubMedCrossRefGoogle Scholar
  3. Baudelaire, C. (1996) Les Paradis Artificiels. Citadel Press Books, Carol Publishing Group, New YorkGoogle Scholar
  4. Bhattacharyya, S., Fusar-Poli, P., Borgwardt, S., Martin-Santos, R., Nosarti, C., O’Carroll, C., et al. (2009). Modulation of mediotemporal and ventrostriatal function in humans by delta9-tetrahydrocannabinol: A neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry, 66(4), 442–451.PubMedCrossRefGoogle Scholar
  5. Booth, M. (2003). Cannabis: A history. Berkshire: Cox and Wyman.Google Scholar
  6. Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., et al. (2008). Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biological Psychiatry, 64(11), 966–973.PubMedCrossRefGoogle Scholar
  7. Bossong, M. G., van Berckel, B. N., Boellaard, R., Zuurman, L., Schuit, R. C., Windhorst, A. D., et al. (2009). Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology, 34(3), 759–766.PubMedCrossRefGoogle Scholar
  8. Cheer, J. F., Wassum, K. M., Sombers, L. A., Heien, M. L., Ariansen, J. L., Aragona, B. J., et al. (2007). Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. The Journal of Neuroscience, 27(4), 791–795.PubMedCrossRefGoogle Scholar
  9. Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annual Review of Neuroscience, 29, 37–76.PubMedCrossRefGoogle Scholar
  10. Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., et al. (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology, 29(2), 417–426.PubMedCrossRefGoogle Scholar
  11. D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry, 57(6), 594–608.PubMedCrossRefGoogle Scholar
  12. D’Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29(8), 1558–1572.PubMedCrossRefGoogle Scholar
  13. ffytche, D. H. (2008). The hodology of hallucinations. Cortex, 44(8), 1067–1083.PubMedCrossRefGoogle Scholar
  14. ffytche, D. H., Howard, R. J., Brammer, M. J., David, A., Woodruff, P., & Williams, S. (1998). The anatomy of conscious vision: An fMRI study of visual hallucinations. Nature Neuroscience, 1(8), 738–742.PubMedCrossRefGoogle Scholar
  15. Ford, J. M., Roach, B. J., Jorgensen, K. W., Turner, J. A., Brown, G. G., Notestine, R., et al. (2009). Tuning in to the voices: A multisite FMRI study of auditory hallucinations. Schizophrenia Bulletin, 35(1), 58–66.PubMedCrossRefGoogle Scholar
  16. Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., et al. (2009). Distinct effects of delta 9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry, 66(1), 95–105.PubMedCrossRefGoogle Scholar
  17. Gillespie, D., & Frase, A. (2009). To be, or not…to bop. Minneapolis: University of Minnesota Press.Google Scholar
  18. Goldsmith, S. K., Shapiro, R. M., & Joyce, J. N. (1997). Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Archives of General Psychiatry, 54(7), 649–658.PubMedCrossRefGoogle Scholar
  19. Grant, I., Gonzalez, R., Carey, C. L., Natarajan, L., & Wolfson, T. (2003). Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. Journal of the International Neuropsychological Society, 9(5), 679–689.PubMedCrossRefGoogle Scholar
  20. Grotenhermen, F. (2005). Cannabinoids. Current Drug Targets. CNS and Neurological Disorders, 4(5), 507–530.PubMedCrossRefGoogle Scholar
  21. Harpaz, Y., Levkovitz, Y., & Lavidor, M. (2009). Lexical ambiguity resolution in Wernicke’s area and its right homologue. Cortex, 45(9), 1097–1103.PubMedCrossRefGoogle Scholar
  22. Harris, D., & Batki, S. L. (2000). Stimulant psychosis: Symptom profile and acute clinical course. The American Journal on Addictions, 9(1), 28–37.PubMedCrossRefGoogle Scholar
  23. Hall, W., & Babor, T. F. (2000). Cannabis use and public health: assessing the burden. Addiction 95, 485–490.PubMedCrossRefGoogle Scholar
  24. Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H. U., et al. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal, 330(7481), 11.PubMedCrossRefGoogle Scholar
  25. Hides, L., Lubman, D. I., Buckby, J., Yuen, H. P., Cosgrave, E., Baker, K., et al. (2009). The association between early cannabis use and psychotic-like experiences in a community adolescent sample. Schizophrenia Research, 112(1–3), 130–135.PubMedCrossRefGoogle Scholar
  26. Hubl, D., Koenig, T., Strik, W. K., Garcia, L. M., & Dierks, T. (2007). Competition for neuronal resources: How hallucinations make themselves heard. The British Journal of Psychiatry, 190, 57–62.PubMedCrossRefGoogle Scholar
  27. Isbell, H., Gorodetzsky, C. W., Jasinski, D., Claussen, U., von Spulak, F., & Korte, F. (1967). Effects of (–)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia, 11(2), 184–188.PubMedCrossRefGoogle Scholar
  28. Jager, G., van Hell, H. H., de Win, M. M., Kahn, R. S., van den Brink, W., van Ree, J. M., et al. (2007). Effects of frequent cannabis use on hippocampal activity during an associative memory task. European Neuropsychopharmacology, 17(4), 289–297.PubMedCrossRefGoogle Scholar
  29. Jung-Beeman, M. (2005). Bilateral brain processes for comprehending natural language. Trends in Cognitive Sciences, 9(11), 512–518.PubMedCrossRefGoogle Scholar
  30. Kane, J. M., Aguglia, E., Altamura, A. C., Ayuso Gutierrez, J. L., Brunello, N., Fleischhacker, W. W., et al. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. European Neuropsy­chopharmacology, 8(1), 55–66.PubMedCrossRefGoogle Scholar
  31. Kapur, S., Arenovich, T., Agid, O., Zipursky, R., Lindborg, S., & Jones, B. (2005). Evidence for onset of antipsychotic effects within the first 24 hours of treatment. The American Journal of Psychiatry, 162(5), 939–946.PubMedCrossRefGoogle Scholar
  32. Klosterkotter, J., Hellmich, M., Steinmeyer, E. M., & Schultze-Lutter, F. (2001). Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58(2), 158–164.PubMedCrossRefGoogle Scholar
  33. Koethe, D., Gerth, C. W., Neatby, M. A., Haensel, A., Thies, M., Schneider, U., et al. (2006). Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophrenia Research, 88(1–3), 142–150.PubMedCrossRefGoogle Scholar
  34. Kuepper, R., Morrison, P. D., van Os, J., Murray, R. M., Kenis, G., & Henquet, C. (2010). Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophrenia Research, 121(1–3):107–117.PubMedCrossRefGoogle Scholar
  35. Lupica, C. R., & Riegel, A. C. (2005). Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuro­pharmacology, 48(8), 1105–1116.PubMedCrossRefGoogle Scholar
  36. Mason, O., Morgan, C. J., Dhiman, S. K., Patel, A., Parti, N., & Curran, H. V. (2009). Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychological Medicine, 39(6), 951–956.PubMedCrossRefGoogle Scholar
  37. Mason, O. J., Morgan, C. J., Stefanovic, A., & Curran, H. V. (2008). The psychotomimetic states inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia Research, 103(1–3), 138–142.PubMedCrossRefGoogle Scholar
  38. McKetin, R., McLaren, J., Lubman, D. I., & Hides, L. (2006). The prevalence of psychotic symptoms among methamphetamine users. Addiction, 101(10), 1473–1478.PubMedCrossRefGoogle Scholar
  39. Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370(9584), 319–328.PubMedCrossRefGoogle Scholar
  40. Morrison, P. D., Zois, V., McKeown, D. A., Lee, T. D., Holt, D. W., Powell, J. F., et al. (2009). The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 39(10), 1607–1616.PubMedCrossRefGoogle Scholar
  41. Murray, R. M., Morrison, P. D., Henquet, C., & Di Forti, M. (2007). Cannabis, the mind and society: The hash realities. Nature Reviews. Neuroscience, 8(11), 885–895.PubMedCrossRefGoogle Scholar
  42. Oertel, V., Rotarska-Jagiela, A., van de Ven, V. G., Haenschel, C., Maurer, K., & Linden, D. E. (2007). Visual hallucinations in schizophrenia investigated with functional magnetic resonance imaging. Psychiatry Research, 156(3), 269–273.PubMedCrossRefGoogle Scholar
  43. O’Leary, D. S., Block, R. I., Koeppel, J. A., Flaum, M., Schultz, S. K., Andreasen, N. C., et al. (2002). Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology, 26(6), 802–816.PubMedCrossRefGoogle Scholar
  44. Pertwee, R. G. (2006). The pharmacology of cannabinoid receptors and their ligands: An overview. International Journal of Obesity, 30(Suppl 1), S13–S18.PubMedCrossRefGoogle Scholar
  45. Peters, B. D., de Koning, P., Dingemans, P., Becker, H., Linszen, D. H., & de Haan, L. (2009). Subjective effects of cannabis before the first psychotic episode. The Australian and New Zealand Journal of Psychiatry, 43(12), 1155–1162.PubMedCrossRefGoogle Scholar
  46. Scott, J., Martin, G., Bor, W., Sawyer, M., Clark, J., & McGrath, J. (2009). The prevalence and correlates of hallucinations in Australian adolescents: Results from a national survey. Schizophrenia Research, 107(2–3), 179–185.PubMedCrossRefGoogle Scholar
  47. Stefanis, N. C., Delespaul, P., Henquet, C., Bakoula, C., Stefanis, C. N., & van Os, J. (2004). Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction, 99(10), 1333–1341.PubMedCrossRefGoogle Scholar
  48. Svizenska, I., Dubovy, P., & Sulcova, A. (2008). Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures—A short review. Pharmacology, Biochemistry, and Behavior, 90(4), 501–511.PubMedCrossRefGoogle Scholar
  49. Tart, C. T. (1971). On being stoned: A psychological study of marijuana intoxication. Palo Alto: Science and Behavior Books.Google Scholar
  50. van Os, J., Bak, M., Hanssen, M., Bijl, R. V., de Graaf, R., & Verdoux, H. (2002). Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology, 156(4), 319–327.PubMedCrossRefGoogle Scholar
  51. Verdejo-Garcia, A., Lopez-Torrecillas, F., Gimenez, C. O., & Perez-Garcia, M. (2004). Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. Neuropsychology Review, 14(1), 1–41.PubMedCrossRefGoogle Scholar
  52. Verdoux, H., Gindre, C., Sorbara, F., Tournier, M., & Swendsen, J. D. (2003). Effects of cannabis and psychosis vulnerability in daily life: An experience sampling test study. Psychological Medicine, 33(1), 23–32.PubMedCrossRefGoogle Scholar
  53. Vernaleken, I., Cumming, P., & Grunder, G. (2008). Imaging studies—Differential action of typical and atypical antipsychotics in a network perspective. Pharmacopsychiatry, 41(Suppl 1), S60–S69.PubMedCrossRefGoogle Scholar
  54. Waters, F. A., Badcock, J. C., & Maybery, M. T. (2006a). The ‘who’ and ‘when’ of context memory: Different patterns of association with auditory hallucinations. Schizophrenia Research, 82(2–3), 271–273.PubMedCrossRefGoogle Scholar
  55. Waters, F. A., Badcock, J. C., Maybery, M. T., & Michie, P. T. (2003). Inhibition in schizophrenia: Association with auditory hallucinations. Schizophrenia Research, 62(3), 275–280.PubMedCrossRefGoogle Scholar
  56. Waters, F. A., Badcock, J. C., Michie, P. T., & Maybery, M. T. (2006b). Auditory hallucinations in schizophrenia: Intrusive thoughts and forgotten memories. Cognitive Neuropsychiatry, 11(1), 65–83.PubMedCrossRefGoogle Scholar
  57. Winton-Brown, T., Allen, P., Bhattacharrya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A., et al. (2011). Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: An fMRI study. Neuropsychopharmacology, 36(7), 1340–1348.PubMedCrossRefGoogle Scholar
  58. Yucel, M., Solowij, N., Respondek, C., Whittle, S., Fornito, A., Pantelis, C., et al. (2008). Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry, 65(6), 694–701.PubMedCrossRefGoogle Scholar
  59. Zuardi, A. W. (2008). Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria, 30(3), 271–280.PubMedCrossRefGoogle Scholar
  60. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Moreira, F. A., & Guimaraes, F. S. (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research, 39(4), 421–429.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Psychosis Studies, Institute of PsychiatryKing’s College LondonLondonUK

Personalised recommendations